Prashni Paliwal

Flatiron Health (United States) — United States

Medicine · Health Sciences

27h-index4.3kcitations52works1.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(10), Prostate Cancer Treatment and Research(8), Chronic Myeloid Leukemia Treatments(8), Glioma Diagnosis and Treatment(6), Cancer Immunotherapy and Biomarkers(6)

Publications52 total

A Phase 1 Trial of Valemetostat in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)
Clinical Lymphoma Myeloma & Leukemia·2024
AML-385 A Phase 1 Trial of Valemetostat in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)
Clinical Lymphoma Myeloma & Leukemia·2024· 1 cited
Real-world clinical efficacy of epidermal growth factor receptor inhibitors (EGFRi) in patients with early-onset (eo), metastatic colorectal cancer (mCRC).
Journal of Clinical Oncology·2024· 3 cited
Supplementary Data from Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors
2023Open Access
Data from Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors
2023Open Access
Data from Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Data from Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors
2023Open Access
Abstract P2-13-03: Feasibility of generating an external control comparator using RWD by matching with previously conducted RCTs: CDK4/6 Inhibitors for the treatment of Metastatic Breast Cancer
Cancer Research·2023
Abstract P2-11-05: Generating real-world external comparators for randomized clinical trials (RCTs) in metastatic breast cancer (mBC) using electronic health records (EHRs)
Cancer Research·2022
Trends in diagnosis and treatment of early breast cancer (eBC) in the United States (US) during the COVID-19 era.
Journal of Clinical Oncology·2021
ATIM-19. POPULATION PHARMACOKINETIC (PPK) ANALYSIS OF NIVOLUMAB FLAT AND WEIGHT-BASED DOSING REGIMENS AND ASSOCIATIONS WITH SAFETY IN PATIENTS WITH RECURRENT GLIOBLASTOMA (rGBM) TREATED IN CHECKMATE 143
Neuro-Oncology·2017Open Access
Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143
Neuro-Oncology·2017· 478 citedOpen Access
Nivolumab (nivo) in combination with radiotherapy (RT) ± temozolomide (TMZ): Updated safety results from CheckMate 143 in pts with methylated or unmethylated newly diagnosed glioblastoma (GBM)
Annals of Oncology·2017· 20 citedOpen Access
ATIM-16. NIVOLUMAB COMBINED WITH RADIOTHERAPY WITH OR WITHOUT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA: RESULTS FROM PHASE 1 SAFETY COHORTS IN CHECKMATE 143
Neuro-Oncology·2016· 9 citedOpen Access
Elotuzumab in combination with thalidomide and low‐dose dexamethasone: a phase 2 single‐arm safety study in patients with relapsed/refractory multiple myeloma
British Journal of Haematology·2016· 46 citedOpen Access
A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498.
Journal of Clinical Oncology·2016· 52 cited
Safety and activity of nivolumab (nivo) monotherapy and nivo in combination with ipilimumab (ipi) in recurrent glioblastoma (GBM): Updated results from checkmate-143.
Journal of Clinical Oncology·2016· 42 cited
Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study
Clinical Lymphoma Myeloma & Leukemia·2015· 69 citedOpen Access
Preliminary safety and activity of nivolumab and its combination with ipilimumab in recurrent glioblastoma (GBM): CHECKMATE-143.
Journal of Clinical Oncology·2015· 69 cited
Pharmacokinetics and Safety of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma and Various Levels of Renal Function: Results of a Phase 1b Study
Blood·2014· 4 cited
page 1 of 3Next →

Frequent Co-authors

Rajita Sinha(9), Géralyn C. Trudel(9), Michael Lim(7), Edwin M. Posadas(7), Antonio Omuro(6), Timothy F. Cloughesy(6), David A. Reardon(6), John H. Sampson(6), George Wilding(6), Gordana Vlahovic(5), Solmaz Sahebjam(5), Joachim M. Baehring(5), Patricia Lo Russo(5), Iain R. Macpherson(5), Valerie G. Brunton(5), Maurizio Voi(5), Robert Latek(4), Ricardo Zwirtes(4), Lewis C. Strauss(4), John C. Araujo(4)